Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease

Joseph L. Price, Daniel W. McKeel, Virginia D. Buckles, Catherine M. Roe, Chengjie Xiong, Michael Grundman, Lawrence A. Hansen, Ronald C. Petersen, Joseph E. Parisi, Dennis W. Dickson, Charles D. Smith, Daron G. Davis, Frederick A. Schmitt, William R. Markesbery, Jeffrey Kaye, Roger Kurlan, Christine Hulette, Brenda F. Kurland, Roger Higdon, Walter KukullJohn C. Morris

Research output: Contribution to journalArticlepeer-review

498 Scopus citations


Objective: To determine the frequency and possible cognitive effect of histological Alzheimer's disease (AD) in autopsied older nondemented individuals. Design: Senile plaques (SPs) and neurofibrillary tangles (NFTs) were assessed quantitatively in 97 cases from 7 Alzheimer's Disease Centers (ADCs). Neuropathological diagnoses of AD (npAD) were also made with four sets of criteria. Adjusted linear mixed models tested differences between participants with and without npAD on the quantitative neuropathology measures and psychometric test scores prior to death. Spearman rank-order correlations between AD lesions and psychometric scores at last assessment were calculated for cases with pathology in particular regions. Setting: Washington University Alzheimer's Disease Research Center. Participants: Ninety-seven nondemented participants who were age 60 years or older at death (mean = 84 years). Results: About 40% of nondemented individuals met at least some level of criteria for npAD; when strict criteria were used, about 20% of cases had npAD. Substantial overlap of Braak neurofibrillary stages occurred between npAD and no-npAD cases. Although there was no measurable cognitive impairment prior to death for either the no-npAD or npAD groups, cognitive function in nondemented aging appears to be degraded by the presence of NFTs and SPs. Conclusions: Neuropathological processes related to AD in persons without dementia appear to be associated with subtle cognitive dysfunction and may represent a preclinical stage of the illness. By age 80-85 years, many nondemented older adults have substantial AD pathology.

Original languageEnglish
Pages (from-to)1026-1036
Number of pages11
JournalNeurobiology of Aging
Issue number7
StatePublished - Jul 2009


  • Neuropathological Alzheimer's disease
  • Nondemented aging
  • Preclinical Alzheimer's disease


Dive into the research topics of 'Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease'. Together they form a unique fingerprint.

Cite this